Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)
Nanjing, CN
Nanjing Hicin Pharmaceutical Co., Ltd. (NHPC), established in 2003 and headquartered in Nanjing, China, operates as a comprehensive enterprise specializing in the research, development, production, marketing, and distribution of pharmaceutical preparations and synthetic chemicals within China. The company boasts a diverse product portfolio, addressing various therapeutic areas such as antivirals, antibiotics, endocrine regulators, gastrointestinal treatments, orthopedic medications, cardiovascular and cerebrovascular drugs, and immunomodulatory agents. Beyond its core pharmaceutical activities, NHPC also provides technology transfer services. On an international scale, Nanjing Hicin Pharmaceutical Co., Ltd. is a supplier of Active Pharmaceutical Ingredients (APIs). Its export offerings specifically include injectable forms of omeprazole sodium and cefepime hydrochloride, along with lansoprazole tablets, which reach markets across South Asia, South America, and Europe.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.20% | -6.68% | -18.38% | -22.96% | -37.61% | -31.30% | +21.56% | +34.24% | +72.93% | +223.34% | +223.34% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+33.1% ★ Q1'26: +12.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+2.9% Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.3% Q1'26: -1.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.0% Q1'26: +11.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.6% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.04× Q1'26: 4.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
711.91M
est: 711.00M (+0.1%)
|
924.54M
est: 1.00B (-7.7%)
|
| EBITDA |
116.85M
est: 191.45M (-39.0%)
|
147.88M
est: 269.68M (-45.2%)
|
| EBIT |
100.09M
est: 133.34M (-24.9%)
|
120.20M
est: 187.82M (-36.0%)
|
| Net Income |
83.22M
|
97.26M
|
| SGA |
464.51M
est: 384.59M (+20.8%)
|
566.35M
est: 541.72M (+4.5%)
|
| EPS |
0.69
|
0.81
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guangyao Liu | Deputy General Manager | — | male |
| Jian Ren Chen | Financial Director | — | male |
| Li Qun Wang | Secretary & Deputy GM | — | male |
| Mingsheng Feng | Deputy GM & Director | — | male |
| Wei Biao Yue | Deputy General Manager | — | male |
| Xiaowei Li | Accounting Supervisor | — | — |
| Yuping Cao | GM & Chairman of the Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300584.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
